Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide and Y-90 Microspheres in Metastatic GI NETs
NCT02859064Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2017
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lanreotide in gastrointestinal neuroendocrine tumors, sponsored by SCRI Development Innovations. Started Jul 2017; status: terminated.
02
Drugs
lanreotide
03
Conditions
gastrointestinal neuroendocrine tumors
Beyond the preview
Go deeper on NCT02859064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859064.